摘要:
The present invention provides compositions and methods for controlling an helminth or arthropod pest. In a preferred embodiment of the invention provided herein, the compositions comprise compounds which alter the 5-HT3 receptor of the pest. Also claimed are various esters of N-methyl 8-azabicyclo[3.2.1]octan-3-ol (tropan-3-yl esters) and an assay for identifying and/or assessing a helminth and/or arthropod control compound by determining the ability of a candidate compound to modulate the activity of a helminth or arthropod 5-HT3 receptor.
摘要:
This invention relates to novel substituted amine derivatives of general formula (I) and a pharmaceutical composition comprising these compounds. In a further aspect the invention provides a method of treatment, prevention or alleviation of a disease, a disorder or a condition of a living animal body, including human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention. The diseases, disorders or conditions to be treated are especially depression, pseudodementia, Ganser’s syndrome, obsessive compulsive disorders, panic disorders, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety or eating disorders.
摘要:
In a preferred embodiment, the subject invention concerns novel analogs of oxybutynin. The present invention also concerns methods for synthesizing the oxybutynin analogs of the present invention. The invention also pertains to methods for treating patients suffering from incontinence and other conditions.
摘要:
Compounds of general formula (1) and pharmacologically acceptable salts thereof: [wherein R 1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R 2 represents a hydrogen atom or a halogen atom; R 3 represents a hydrogen atom, an alkyl group which may be substituted, an aralkyl group, an alkylcarbonyl group which may be substituted, an alkylsulfonyl group which may be substituted or the like; each of R 4 and R 5 represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted, a carbamoyl group or the like; R 6 represents a heterocycle or the like; each of R 7 and R 8 represents a hydrogen atom, an alkyl group or the like; n represents 0, 1 or 2] exhibit excellent activated blood coagulation factor X inhibitory activity and are useful for the prevention or treatment of blood coagulation-related diseases.
摘要翻译:通式(1)的化合物及其药理上可接受的盐:[其中R1代表氢原子,卤素原子,烷基或羟基; R2代表氢原子或卤素原子; R3代表氢原子,可被取代的烷基,芳烷基,可被取代的烷基羰基,可被取代的烷基磺酰基等; R 4和R 5各自表示氢原子,卤素原子,可被取代的烷基,氨基甲酰基等; R6代表杂环等; R 7和R 8中的每一个表示氢原子,烷基等; n表示0,1或2]表现出优异的活化凝血因子X抑制活性,并且可用于预防或治疗凝血相关疾病。
摘要:
Die Erfindung betrifft ein Verfahren zum Herstellen von endo-Nortropin unter Verwendung von 8-Benzyl-nortropan-3-on-perchlorat, sowie letzteres selbst. Das endo-Nortropin ist das Schlüsselprodukt zur Herstellung der wichtigen Azoniaspironortropanolester, die als Pharmazeutika, insbesondere Spasmolytika, eingesetzt werden. Prinzipiell gibt es drei verschiedene Synthesewege zur Herstellung dieses Zwischenproduktes, die unterschiedliche Nachteile mit sich bringen. Die Erfindung schafft hier Abhilfe durch die zweistufige Behandlung von 8-Benzyl-nortropan-3-on-perchlorat mit katalytisch erregtem Wasserstoff, wobei man das Startprodukt zunächst in wässriger Suspension bei atmosphärischem Druck und Raumtemperatur mit einem Palladium-Katalysator vorhydriert, am Ende der Reaktion den Katalysator durch Filtration zurückgewinnt, das Filtrat über einen Anionenaustauscher schickt und die nunmehr alkalisch reagierende Lösung mit durch Raney-Nickel erregtem Wasserstoff bei atmosphärischem Druck und Raumtemperatur bei 1000 - 1500 Umdrehungen pro Minute turbuliert. Dieser neue Syntheseweg über den neuen Stoff des Perchloratsalzes als Zwischenprodukt ist äußerst wirtschaftlich und umweltfreundlich und liefert praktisch vollständig stereoselektiv die gewünschte endo-form des Nortropins.
摘要:
New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8-carbo and 8-oxy tropanes having 6- or 7-substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
摘要:
The present invention relates to 2-aminopyridine derivatives of formula (I) wherein G, R?1 and R2¿ are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.
摘要:
Sulphonamide compounds of formula (I) or a salt thereof, wherein: Ar is an optionally substituted mono- or bicyclic aromatic or heteroaromatic ring; R?1 and R2¿ are independently hydrogen, C¿1-6? alkyl, arylC1-6 alkyl or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from nitrogen, sulphur or oxygen, the nitrogen atom being substituted by hydrogen, C1-6 alkyl, cycloC3-7alkyl, or an optionally substituted aryl, heteroaryl or arylC1-6 alkyl group; R?3¿ is hydrogen or C¿1-6? alkyl; X is oxygen, sulphur or a bond; n is 2 or 3; and m is 1 or 2, having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of CNS disorders.
摘要:
A compound having formula (I) or any of its enantiomers of any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; and R4 is phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF¿3?, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; 3,4-methylenedioxyphenyl; benzyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; heteroaryl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; or naphtyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl. The compounds possess valuable pharmaceutical properties as monoamine neurotransmitter re-uptake inhibitors.